Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo UCB
Engages in the research, development, and commercialization of pharmaceutical and biotechnology products

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.

It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec.

The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Number of employees : 7 563 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Cimzia®1,08327.9%1,30731.3% +20.68%
Keppra® (including Keppra® XR)737.0019%724.0017.3% -1.76%
Vimpat®679.0017.5%814.0019.5% +19.88%
Other Products431.0011.1%329.007.9% -23.67%
Neupro®258.006.7%302.007.2% +17.05%
Zyrtec® (including Zyrtec-D®/Cirrus®)147.003.8%140.003.4% -4.76%
Xyzal®117.003%107.002.6% -8.55%
Venlaflaxine XR90.002.3%90.002.2% 0%
Nootropil®52.001.3%46.001.1% -11.54%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
United States1,69443.7%1,85144.3% +9.27%
Other Countries485.0012.5%319.007.6% -34.23%
Germany247.006.4%290.006.9% +17.41%
Japan207.005.3%268.006.4% +29.47%
Other196.005.1%292.007% +48.98%
Emerging Markets192.005%---
Italy154.004%154.003.7% 0%
Spain152.003.9%162.003.9% +6.58%
France150.003.9%161.003.9% +7.33%
Belgium35.000.9%33.000.8% -5.71%
Europe--328.007.9%-
Managers
NameAgeSinceTitle
Jean-Christophe Tellier-2011Chief Executive Officer & Executive Director
Evelyn du Monceau671984Chairman
Charl van Zyl, MBA502017Chief Operating Officer
Detlef Thielgen-2006Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich MD, PhD572006Chief Medical Officer & Executive Vice President
Ismail Kola, PhD602009Chief Scientific Officer, EVP & Head-New Medicines
Norman J. Ornstein-2008Independent Director
Albrecht de Graeve622010Independent Director
Charles-Antoine Janssen-2001Director
Jonkheer Cédric van Rijckevorsel, CFA-2014Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 194,505,658 114,788,778 59.0% 6,419,669 3.3% 59.0%
Shareholders
NameEquities%
Financière de Tubize SA 68,076,981 35.0%
Wellington Management Co. LLP 14,194,483 7.30%
Capital Research & Management Co. (World Investors) 7,290,799 3.75%
UCB SA 6,428,833 3.31%
The Vanguard Group, Inc. 3,011,933 1.55%
Capital Research & Management Co. (Global Investors) 2,857,264 1.47%
Schroder Investment Management Ltd. 2,516,580 1.29%
Schwarz Family 2,471,404 1.27%
BlackRock Fund Advisors 2,281,766 1.17%
Norges Bank Investment Management 1,994,994 1.03%
Holdings
NameEquities%Valuation
UCB (UCB) 6,428,8333.31%468,004,449 USD
Dermira Inc (DERM) 1,841,2344.42%49,289,834 USD
Arix Bioscience PLC (ARIX) 3,869,9024.03%9,815,581 USD
Heidelberg Pharma AG (WL6) 1,132,8085.05%4,037,135 USD
Markets and indexes
- Euronext Brussels
- Compartiment A
- BEL 20 / Euronext 100, PEA
Stock Exchange Codes
- Bloomberg Code :  UCB:BB
- Reuters Code :  UCB.BR
- Datastream Code :  B:UCB
Company contact information
UCB
allée de la Recherche 60
BE-1070 Bruxelles, Bruxelles-Capitale
Belgium

Phone : +32 (0)2 559 9999
Fax : +32 (0)2 559 9900
Internet : http://www.ucb.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
UCB5.30%14 668
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559
AMGEN22.20%127 332
SANOFI-4.75%108 784
NOVO NORDISK A/S29.05%102 185
BRISTOL-MYERS SQUIBB COMPANY6.13%102 163
BAYER5.77%101 894
ELI LILLY AND COMPANY17.01%95 190
ABBOTT LABORATORIES42.31%95 106
GLAXOSMITHKLINE-18.34%84 764
CELGENE CORPORATION-11.40%83 526
ASTRAZENECA6.41%81 598
ALLERGAN PLC-21.78%55 807
SHIRE-24.58%44 705
TAKEDA PHARMACEUTICAL CO LTD27.43%42 944
CHUGAI PHARMACEUTICAL CO LTD78.24%29 496
JIANGSU HENGRUI MEDICINE CO LTD43.69%27 842
Connections : UCB
Telenet Group BVBA
Hoechst Marion Roussel, Inc.
Belgian Luxembourg Chamber of Commerce for Russia & Belarus
FBNet Belgium
The Belgische Commissie Corporate Governance
Pharmaceutical Research & Manufacturers of America
European Federation of Pharmaceutical Industries & Assns
Johann Wolfgang Goethe-Universität Frankfurt am Main
Concours Reine Elisabeth
International Business Leaders Advisory Council
Flanders-China Chamber of Commerce
SCR-Sibelco NV
Biotechnology Innovation Organization
Wallon Institute for Life Lead Sciences
Alcatel Trade International AG
U.S. Capitol Historical Society
The Conference Board, Inc.
Astex Therapeutics Ltd.
Université Libre de Bruxelles
Ucb Pharma OY Finland
IDS Capital (UK) Ltd.
The Campaign Legal Center
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem